GlobeNewswire Inc.··PatentvestLilly's Retatrutide Hits Surgery-Level Weight Loss, But IP Wars Loom
Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.
PFELLYSNYNVOintellectual propertyweight loss